Expertise in
15
conditions

Dr. Matthen Mathew

Oncology
Baptist Health Lynn Cancer Institute | Delray
6282 Linton Blvd, 
Delray Beach, FL 
Accepting New Patients
Offers Telehealth
Expertise in
15
conditions
Baptist Health Lynn Cancer Institute | Delray
6282 Linton Blvd, 
Delray Beach, FL 

Overview

Matthen Mathew is an Oncologist practicing medicine in Delray Beach, Florida.

Dr. Mathew is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Lung Adenocarcinoma, Non-Small Cell Lung Cancer (NSCLC), and Tissue Biopsy.

He is actively involved in clinical research, co-authoring 6 peer reviewed articles and participating in 7 clinical trials. Dr. Mathew is currently accepting new patients.

Graduate Institution

University Of Florida College Of Medicine

Specialties

Oncology

Licenses

Internal Medicine in NY

Hospital Affiliations

Boca Raton Regional Hospital
Bethesda Hospital East
Delray Medical Center
Hca Florida Jfk Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Baptist Health Lynn Cancer Institute | Delray
6282 Linton Blvd, Delray Beach, FL 33484
Other Locations
Baptist Health Lynn Cancer Institute | Boca Raton
701 NW 13th St, Boca Raton, FL 33486

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Cisplatin, Fluorouracil, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: August 27, 2026
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
An Open-Label, Phase II Multicenter Study of Rituximab or Tocilizumab for Steroid-Dependent Immune-Related Adverse Events Due to Immune Checkpoint Blockade
An Open-Label, Phase II Multicenter Study of Rituximab or Tocilizumab for Steroid-Dependent Immune-Related Adverse Events Due to Immune Checkpoint Blockade
Enrollment Status: Active_not_recruiting
Publish Date: August 03, 2026
Intervention Type: Drug
Study Phase: Phase 2
A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination With Anticancer Agents in Subjects With Selected Advanced Solid Tumors
A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination With Anticancer Agents in Subjects With Selected Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase I/II, Open-label, Two Part Study of GSK3359609 in Combination With Tremelimumab in Participants With Selected, Advanced Solid Tumors
A Phase I/II, Open-label, Two Part Study of GSK3359609 in Combination With Tremelimumab in Participants With Selected, Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: August 28, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Tremelimumab, Docetaxel, Paclitaxel, Cetuximab
Study Phase: Phase 1/Phase 2
A Single-arm, Phase II Study of Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in Resectable Non-small Cell Lung Cancer (NSCLC)
A Single-arm, Phase II Study of Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in Resectable Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: December 12, 2023
Intervention Type: Drug
Study Drugs: MPDL3280A, Carboplatin, Nab-Paclitaxel
Study Phase: Phase 2
A Phase 2 Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Adults With Head and Neck Cancer
A Phase 2 Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Adults With Head and Neck Cancer
Enrollment Status: Terminated
Publish Date: January 03, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

6 Total Publications

INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors.
INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors.
Journal: Cancer immunology, immunotherapy : CII
Published: August 31, 2023
Similar Doctors
Expertise in
18
conditions
Dr. Sanoj Punnen
Oncology | Urology
Expertise in
18
conditions
Dr. Sanoj Punnen
Oncology | Urology
Referral may be required
1192 East Newport Center Drive, 
Deerfield Beach, FL 
 (9.6 miles away)
305-243-6090
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Punnen's research interest is in prostate cancer, primarily related to imaging, genomic, and molecular biomarkers in the detection, risk stratification, and monitoring of prostate cancer. Dr. Punnen is a lead investigator on two prospective clinical trials validating a novel blood-based biomarker called the 4KScore test for predicting the risk of clinically significant prostate cancer and need for biopsy of the prostate. He is also the Principal Investigator on an ongoing NCI funded prospective clinical trial examining the impact of prostate MRI and tissue based genomic prognostic signatures in men undergoing active surveillance for prostate cancer. Dr. Punnen is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Bladder Cancer, Prostatectomy, and Cystectomy. Dr. Punnen is currently accepting new patients.

Expertise in
57
conditions
Dr. Ricardo J. Komotar
Oncology | Neurosurgery
Expertise in
57
conditions
Dr. Ricardo J. Komotar
Oncology | Neurosurgery
Referral may be required
1295 Northwest 14th Street, 
Miami, FL 
 (45.2 miles away)
305-243-6946
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Ricardo Komotar is an Oncologist and a Neurosurgery provider practicing medicine in Miami, Florida. Dr. Komotar is highly rated in 57 conditions, according to our data. His clinical expertise encompasses Brain Tumor, Meningioma, Glioblastoma, Awake Craniotomy, and Posterior Fossa Decompression. Dr. Komotar is currently accepting new patients.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

Baptist Health Miami Cancer Institute

8900 N Kendall Dr, 
Miami, FL 
 (53.6 miles away)
786-345-7208
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Manmeet Ahluwalia is an Oncologist practicing medicine in Miami, Florida. Dr. Ahluwalia is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Brain Tumor, Glioblastoma, Astrocytoma, and Glioma. Dr. Ahluwalia is currently accepting new patients.

Frequently Asked Questions about Dr. Matthen Mathew

How do I make an appointment with Dr. Matthen Mathew?

You can book an appointment with Dr. Matthen Mathew by calling their office at 561-666-8479. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Matthen Mathew a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Matthen Mathew is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Matthen Mathew specialize in?

While Dr. Matthen Mathew is a Oncology, they have specific expertise in Lung Cancer, Pleuropulmonary Blastoma, and Lung Adenocarcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Matthen Mathew participate in research or clinical trials?

Yes. Dr. Matthen Mathew has published 6 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Matthen Mathew's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Matthen Mathew accept my insurance?

Dr. Matthen Mathew accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 561-666-8479 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mathew's expertise for a condition
ConditionClose
    View All 9 Distinguished Conditions
    View All 76 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile